E-mail a Wiley Online Library Link

Jerald P. Radich Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia Cancer 118

Version of Record online: 29 JUN 2011 | DOI: 10.1002/cncr.26280

In chronic myeloid leukemia, the objective of current breakpoint cluster region/v-abl Abelson murine leukemia viral oncogene (BCR-ABL) inhibitor therapy is complete cytogenetic response. This review of early data from pivotal dasatinib and nilotinib trials indicated that BCR-ABL inhibitor therapy has produced promising cytogenetic and molecular responses.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field